Hundreds of online sellers are offering an Eli Lilly weight-loss drug that’s years away from regulatory approval: WSJ

Brasil Notícia Notícia

Hundreds of online sellers are offering an Eli Lilly weight-loss drug that’s years away from regulatory approval: WSJ
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Hundreds of online sellers are offering Eli Lilly’ & Co.’s LLY, -2.71% retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory approval, the Wall Street Journal reported Friday based on its own review of the matter. The bulk of the sellers appears to be Chinese who are shipping directly to U.S. consumers from sites such as one called Made-in-China.com. Some of the sites, that appear to be based in the U.S.

15%, In one instance, a fitness influencer is peddling the drug via a newsletter. The report comes after the Journal in August reported that more than 50 sites are selling knockoff versions of semaglutide and tirzepatide, the active ingredients in Ozempic and Mounjaro respectively. Those are diabetes and weight-loss drugs developed by Novo Nordisk NOVO.B, +0.28% and Eli Lilly that have gained FDA approval. The FDA sent warning letters to two websites following the Journal’s article.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

MarketWatch /  🏆 3. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Eli Lilly targets firms that import and sell imitation Mounjaro onlineEli Lilly targets firms that import and sell imitation Mounjaro onlineEli Lilly filed a complaint with the U.S. International Trade Commission to block companies from importing and selling cheaper versions of its hit drug Mounjaro.
Consulte Mais informação »

Black Market for Weight Loss Drug Retatrutide Spreads Online Years Ahead of FDA ApprovalsBlack Market for Weight Loss Drug Retatrutide Spreads Online Years Ahead of FDA ApprovalsEli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound
Consulte Mais informação »

2 Stocks Set to Capitalize on the Surging Weight Loss Drug Trend2 Stocks Set to Capitalize on the Surging Weight Loss Drug TrendStocks Analysis by The Tokenist (Timothy Fries) covering: Eli Lilly and Company, Novo Nordisk A/S. Read The Tokenist (Timothy Fries)'s latest article on Investing.com
Consulte Mais informação »

Sanofi to offer insulin product for $35 to all Americans through GoodRxSanofi to offer insulin product for $35 to all Americans through GoodRxThe effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.
Consulte Mais informação »

Sanofi to offer insulin product for $35 to all Americans through GoodRxSanofi to offer insulin product for $35 to all Americans through GoodRxThe effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.
Consulte Mais informação »

‘Thanksgiving’ Teaser — Scares Are on the Menu‘Thanksgiving’ Teaser — Scares Are on the MenuEli Roth's holiday horror flick Thanksgiving, starring Patrick Dempsey, has released a new teaser.
Consulte Mais informação »



Render Time: 2025-02-27 01:28:53